The Russian Industry Ministry announced on Monday that the Russian BIOCAD company and the Egyptian Pharma Group signed a contract for US$42.7 million to supply Egypt with the Russian cancer treatment drug Rituximab.
Rituximab is a monoclonal antibody that clinical studies have proven is no different to the original Mabthera drug.
The contract, which was signed on September 3 in Petersburg, Russia during a visit by an Egyptian delegation, is effective for five years, renewable.
BIOCAD has signed contracts worth $500 million with several parties over the past two years, supplying them with monoclonal antibodies, such as Bevacizumab and Trastuzumab.
Edited translation from Al-Masry Al-Youm
